Clinical trials: sponsored by Almirall, S.A.
Atopic Dermatitis, Eczema
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADhope (NCT05990725)
- Testing
- Lebrikizumab
- Where
- 33 sites in Germany, Netherlands and 1 more
- Volunteers
- 260 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.
- Trial name
- ADvantage (NCT05149313)
- Testing
- Lebrikizumab
- Where
- 48 sites in Austria, Belgium and 6 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are…
- Trial name
- PROSES (NCT04820673)
- Testing
- Sarecycline
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.
- Trial name
- NCT02959970
- Testing
- dapsone gel
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
- Trial name
- NCT02320149
- Testing
- Sarecycline
- Where
- 57 sites in United States
- Volunteers
- 968 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
- Trial name
- NCT01628549
- Testing
- 50 mg P005672-HCl, 100 mg P005672-HCl
- Where
- 38 sites in United States
- Volunteers
- 285 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
- Trial name
- NCT02322866
- Testing
- Sarecycline
- Where
- 57 sites in United States
- Volunteers
- 1,034 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
- Trial name
- NCT02413346
- Testing
- Sarecycline
- Where
- 56 sites in United States
- Volunteers
- 490 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
- Trial name
- NCT01974323
- Testing
- Dapsone Gel, Dapsone Gel Vehicle
- Where
- 3 sites in United States, Canada
- Volunteers
- 2,238 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
- Trial name
- NCT01974141
- Testing
- Dapsone Gel, Dapsone Gel Vehicle
- Where
- 2 sites in United States, Canada
- Volunteers
- 2,102 people
- Sponsor
- Almirall, S.A.